Next-Generation Artificial Pancreas: What's in Development

What Is an Artificial Pancreas?

The term "artificial pancreas" sounds futuristic, but the first generation is already here. Today's closed-loop systems — like the Tandem Control-IQ, Omnipod 5, and Medtronic 780G — combine a continuous glucose monitor (CGM) with an insulin pump and an algorithm that automatically adjusts insulin delivery. These systems have transformed diabetes management for hundreds of thousands of people with Type 1 diabetes.

But they're not perfect. They still require manual meal announcements, can lag behind rapid glucose changes, and only deliver insulin — not glucagon. The next generation aims to fix all of that.

What's Actually Being Developed Right Now

1. Fully Automated, No-Meal-Announcement Systems

Current systems work better when you tell them you're about to eat. Researchers are working to eliminate that step entirely. Beta Bionics and its iLet Bionic Pancreas received FDA approval in 2023 and is now commercially available — it requires no carb counting or meal announcements, using only body weight to set up. Studies published in the New England Journal of Medicine confirmed it outperformed standard care on time-in-range metrics. Next-generation algorithms from Tandem (Control-IQ+) and Medtronic (the Simplera sensor paired with 780G) are also working toward simplified, more autonomous operation.

2. Dual-Hormone Systems (Insulin + Glucagon)

One of the biggest limitations of current systems is that they can only lower blood sugar — they can't raise it when hypoglycemia is imminent. A true bihormonal artificial pancreas delivers both insulin and glucagon (or pramlintide), giving it the ability to actively prevent lows, not just reduce insulin.

Beta Bionics is developing a bihormonal version of the iLet. Zealand Pharma's dasiglucagon — a stable liquid glucagon — is being studied as the glucagon component in dual-chamber pump systems. Early clinical trials have shown bihormonal systems reduce hypoglycemia significantly compared to insulin-only closed loop. The challenge remains glucagon stability and the added complexity of a two-hormone delivery device.

3. Faster Insulins and Smarter Algorithms

Even the best algorithm is limited by how quickly insulin works. Ultra-fast insulin analogs — including Lilly's Lyumjev (insulin lispro-aabc) and Novo Nordisk's Fiasp — are being optimized for pump use and are already used in some closed-loop trials. Academic research groups are testing algorithms that incorporate meal photos, heart rate data, and even stress hormones to predict glucose needs before a spike begins.

4. Implantable and Minimally Invasive Sensors

CGM accuracy is the foundation everything else depends on. Senseonics' Eversense 365 — an implantable sensor lasting a full year — received FDA approval and represents a major step toward "set and forget" glucose monitoring. Longer sensor life reduces user burden and could improve closed-loop reliability. Abbott and Dexcom are both developing next-generation sensors with improved accuracy and extended wear times beyond current 10–15 day windows.

5. Fully Implantable Systems

Medtronic's implantable insulin pump (MiniMed Implantable Pump) has existed in limited form for decades, but coupling it with an implantable CGM and automated algorithm remains a significant engineering challenge. Research programs in Europe are exploring fully implanted closed-loop systems for select patient populations, though these remain experimental.

Current Status (2025)

Here's an honest breakdown of where things stand:

• Available now: iLet Bionic Pancreas (no meal announcement), Omnipod 5, Tandem Control-IQ, Medtronic 780G, Eversense 365 implantable CGM
• In late-stage trials: Bihormonal iLet with dasiglucagon, Tandem Control-IQ+ algorithm, Medtronic 780G with Simplera sensor
• Earlier stage / promising: AI-driven predictive algorithms incorporating non-glucose data, fully implantable systems, ultra-long-duration CGM
• Still largely experimental: Closed-loop systems for Type 2 diabetes, pediatric closed-loop under age 2, bihormonal systems at commercial scale

Patients interested in participating in trials can search ClinicalTrials.gov by condition ("Type 1 diabetes closed loop") to find currently enrolling studies near them.

Timeline: When Can Patients Expect These?

• 2025–2026: Improved algorithm updates for existing pumps; expanded Eversense 365 availability; Tandem Control-IQ+ likely FDA submission
• 2026–2028: Bihormonal systems may reach commercial availability if late-stage trials succeed
• 2029 and beyond: Fully implantable closed-loop systems; AI-integrated multi-signal algorithms at scale

These timelines depend on clinical trial outcomes and regulatory approvals — delays are common in medical device development.

What This Means for Patients

If you're managing diabetes today, the most important takeaway is this: the technology available right now is already the best it has ever been, and it's improving every year. If you're on a closed-loop system already, software updates often bring meaningful improvements without new hardware.

If you're not yet on a closed-loop system and are eligible, talking to your endocrinologist about current options — and ensuring you have reliable access to supplies — is the most impactful step you can take. Resources like mdsdiabetes.com can help with CGM and pump supply access while technology continues to advance.

For those hoping for a cure rather than better management tools, closed-loop systems are a bridge — not a destination. But they're a remarkably good bridge, and the next generation is being built right now.